# InflaRx N.V. (IFRX)

Source: https://www.quantisnow.com/company/IFRX
Generated: 2026-11-14T03:02:55.146Z

- Ticker: IFRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2017
- SEC CIK: 0001708688
- Website: inflarx.de

## About

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

## Latest IFRX news and filings

- 2026-11-06 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6778884)
- 2026-11-06 12:30 UTC [InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan](https://www.quantisnow.com/insight/inflarx-announces-publication-of-phase-1-data-demonstrating-favorable-safety-6777982)
- 2026-11-03 21:34 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6770159)
- 2026-11-03 13:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6768628)
- 2026-11-03 12:00 UTC [InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day](https://www.quantisnow.com/insight/inflarx-highlights-izicopan-development-path-and-commercial-opportunity-in-anca-associated-6768336)
- 2026-10-27 11:30 UTC [Conference Announcement] [InflaRx Announces November Investor Events](https://www.quantisnow.com/insight/inflarx-announces-november-investor-events-6758479)
- 2026-10-22 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6755090)
- 2026-10-22 16:00 UTC [InflaRx Highlights Izicopan’s Therapeutic Potential at  Kidney Week 2026](https://www.quantisnow.com/insight/inflarx-highlights-izicopans-therapeutic-potential-at-kidney-week-2026-6754810)
- 2026-10-02 11:30 UTC [InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026](https://www.quantisnow.com/insight/inflarx-to-present-late-breaking-pre-clinical-data-on-izicopan-at-kidney-6733452)
- 2026-10-01 11:30 UTC [Leadership Update] [InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development](https://www.quantisnow.com/insight/inflarx-appoints-gabriela-alperovich-md-phd-as-senior-vice-president-6731388)
- 2026-09-21 11:30 UTC [Conference Announcement] [InflaRx to Host Virtual Capital Markets Day](https://www.quantisnow.com/insight/inflarx-to-host-virtual-capital-markets-day-6721205)
- 2026-09-14 13:05 UTC [Analyst Coverage Initiated] [Needham initiated coverage on InflaRx with a new price target](https://www.quantisnow.com/insight/needham-initiated-coverage-on-inflarx-with-a-new-price-target-6714016)
- 2026-08-20 11:30 UTC [InflaRx Announces Participation in September Investor Conferences](https://www.quantisnow.com/insight/inflarx-announces-participation-in-september-investor-conferences-6689366)
- 2026-08-14 20:21 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by InflaRx N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inflarx-nv-6683113)
- 2026-08-14 12:22 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by InflaRx N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inflarx-nv-6681956)
- 2026-08-13 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-inflarx-nv-6678999)
- 2026-08-06 14:28 UTC [SEC Form SCHEDULE 13G filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-inflarx-nv-6668036)
- 2026-08-06 13:20 UTC [SEC Form F-3 filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-inflarx-nv-6667854)
- 2026-08-06 13:18 UTC [SEC Form S-8] [SEC Form S-8 filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-inflarx-nv-6667851)
- 2026-08-06 11:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6667376)
- 2026-08-06 11:30 UTC [Public Offering] [InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones](https://www.quantisnow.com/insight/inflarx-reports-second-quarter-2026-results-and-highlights-key-achievements-6667265)
- 2026-07-30 11:30 UTC [Earnings Date] [InflaRx to Report Second Quarter 2026 Results on  August 6, 2026](https://www.quantisnow.com/insight/inflarx-to-report-second-quarter-2026-results-on-august-6-6654984)
- 2026-06-30 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6620750)
- 2026-06-30 11:30 UTC [InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos](https://www.quantisnow.com/insight/inflarx-assessing-feasibility-of-broadened-strategy-for-ancaassociated-vasculitis-in-6619928)
- 2026-05-14 12:27 UTC [SEC Form SCHEDULE 13G filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-inflarx-nv-6552616)
- 2026-05-13 11:53 UTC [Analyst Upgrade] [InflaRx upgraded by Raymond James with a new price target](https://www.quantisnow.com/insight/inflarx-upgraded-by-raymond-james-with-a-new-price-target-6549713)
- 2026-05-08 12:15 UTC [Public Offering] [InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares](https://www.quantisnow.com/insight/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-6541127)
- 2026-05-07 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6538648)
- 2026-05-07 12:33 UTC [SEC Form 424B5] [SEC Form 424B5 filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-inflarx-nv-6537826)
- 2026-05-06 20:01 UTC [SEC Form 424B5] [SEC Form 424B5 filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-inflarx-nv-6535115)
- 2026-05-06 12:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6534290)
- 2026-05-06 12:30 UTC [InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares](https://www.quantisnow.com/insight/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-6534238)
- 2026-05-06 12:25 UTC [Earnings Date] [InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases](https://www.quantisnow.com/insight/inflarx-announces-advancement-of-izicopan-in-anca-associated-vasculitis-and-select-6534226)
- 2026-05-06 12:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6534211)
- 2026-05-04 20:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6529328)
- 2026-05-04 11:30 UTC [InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes](https://www.quantisnow.com/insight/inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-6527968)
- 2026-05-01 11:30 UTC [Earnings Date] [InflaRx to Report First Quarter 2026 Results on May 7, 2026](https://www.quantisnow.com/insight/inflarx-to-report-first-quarter-2026-results-on-may-7-6525889)
- 2026-04-28 20:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by InflaRx N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-inflarx-nv-6518832)
- 2026-04-28 11:30 UTC [InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/inflarx-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6517592)
- 2026-04-24 12:32 UTC [Analyst Coverage Resumed] [Oppenheimer resumed coverage on InflaRx with a new price target](https://www.quantisnow.com/insight/oppenheimer-resumed-coverage-on-inflarx-with-a-new-price-target-6513790)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IFRX
- Earnings history: https://www.quantisnow.com/earnings/IFRX
- Dividend history: https://www.quantisnow.com/dividends/IFRX
- Insider transactions: https://www.quantisnow.com/insiders/IFRX
- Options chain: https://www.quantisnow.com/options/IFRX
- SEC 8-K filings only: https://www.quantisnow.com/company/IFRX/8-k
- RSS and alerts for IFRX: https://www.quantisnow.com/docs/rss-feeds.md